Revance Therapeutics Announces Pricing of Public Offering of Common Stock (Revance Therapeutics Inc)

(Source: Revance Therapeutics Inc) NEWARK, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the pricing of its underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $36.00 per share. Revance also granted the underwriters a 30-day option to acquire an additional 487,500 shares from Revance. The offering is expected to close on November 9, 2015, subject to customary closing conditions. Cowen and Company, LLC, Piper Jaffray & Co., and Guggenheim Securities, LLC are acting as book-running managers for the proposed offering, with William Blair & Company, L.L.C., and SunTrust Robinson Humphrey, Inc. acting...